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Mesenchymal  stem  cells  (MSC)  are  adult  stem  cells  present  in  many 
tissues, such as bone marrow, adipose tissue and peripheral blood. They are able 
to differentiate into several mesodermal cells, such as chondrocyte, osteoblast 
and  adipocyte.  In  addition,  MSCs  share  the  same  microenvironment  of 
hematopoietic stem cells (HSC) and they play a central role in the regulation of 
proliferation  and  self-renewal  of  HSCs.  Retinoic  acid  (RA)  is  a  well-known 
morphogen-like agent, is widely used alone or in combination with epigenetic 
modifying  drugs,  such  as  demethylating  agents  and  HDAC  inhibitors,  in 
therapeutic approaches to treat acute myeloid leukemia and solid tumors. Here, 
we test the in vitro effects of all-trans retinoic acid, 5-azacytidine and valproic 
acid  on  the  biological  properties  of  MSCs.  We  show  that  both  VPA  and  AZA 
reduce the number of CFU-Fs by increasing the number of apoptotic cells and 
committing them towards a non-proliferative state. In addition, we demonstrate 
that ATRA treatment exerts opposite effect on CFU-Fs and cultured MSCs, by 
decreasing  colony  formation  of  CFU-Fs  and  enhancing  the  proliferation  of 
cultured MSCs. We demonstrate that ATRA signaling is mediated by the RARβ2 
receptor in both early progenitors and MSCs, and it differentially triggers the 
expression of genes involved in the self-renewal and pluripotency of embryonic 
and adult stem cells. ~ 2 ~ 
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Human mesenchymal stem cells, also known as osteogenic stem cells or 
multipotent mesenchymal stromal cells (Friedenstein 1987, Dominici 2006), were 
first isolated from bone marrow in 1966 for their ability to form discrete colonies 
(the colony-forming unit fibroblastic, CFU-Fs) initiated by single cell when seeded 
at clonal density(Friedenstein 1966). Later experiments of in vivo transplantation 
demonstrated that single MSC generates multiple mesodermic tissue, as bone, 
cartilage, adipose and fibrous tissue. (Friedenstein 1990) 
Further  studies  have  led  to  the  better  characterization  of  MSC  and  the 
identification  of  three  peculiar  criteria  that  define  them:  their  property  of 
adherence  to  plastic;  their  phenotype,  assessed  by  the  expression  of  a 
combination of surface antigens (CD14-, CD19-, CD34-, CD45-, HLA-DR-, CD73+, 
CD90+, CD105+); and their capacity of in vitro differentiation into three lineages, 
chondrocyte, osteoblast and adipocyte. (Dominici 2006) As any other stem cell, 
the  mesenchymal  stem  cell  has  the  ability  to  differentiate  towards  different 
lineages and to perpetuate itself by asymmetrical division. Indeed, MSCs are able 
to  proliferate  in  vitro  and  to  maintain  their  differentiation  potential  after 
multiple population doublings. The use of specific in vitro condition stimulates 
MSC  differentiation  into  different  mesodermal  cells,  such  as  stromal  cells, 
chondrocyte, osteoblast, adipocyte and myocite. (Figure 1)(Friedenstein 1966; 
Pittenger 1999, Caplan 2007). Furthermore, compelling evidence from in vitro 
studies  demonstrate  the  plasticity  of  MSCs,  inducing  them  to  become 
nonmesodermal cells such as neurons, glial cells, hepatocytes, and endothelial 
cells (Abdallah 2008). However, this multilineage differentiation potential is still 
controversial, due to the lack of in vivo evidence.  In addition, the gold standard 
assay  for  demonstration  of  stemcellness  is  based  on  the  ability  of  cells  to 
reconstitute in vivo a stem cell compartment with phenotypic and functional 
properties identical to the original cell population only acquired through in vivo 
transplantation  in  immunocompromised  mice.  Evidence  for  self  renewal  and 
maintenance of stemcellness capacity of MSCs after serial implantation has only 
recently  started  to  emerge,  suggesting  the  presence  of  bona  fide  stem  cell 
characteristics (Sacchetti et al. 2007) 
MSCs are present in different tissues in the organism, and have been isolated 
from tissues other than bone marrow, such as adipose tissue, peripheral blood, ~ 3 ~ 
dental pulp, fetal liver, amniotic fluid or umbilical cord blood. (Lazennec 2008) 
Traditionally, MSCs are isolated by density-gradient fractionation and selected by 
their  ability  to  adhere  on  the  plastic  surface.  However,  they  remain  a 
heterogeneous mixture of cells with a variable differentiation and proliferation 
potential.  For  example,  only  around  30%  of  the  clonal  MSCs  (ie  CFU-F)  are 
multipotent  and  able  to  form  bone  after  in  vivo  transplantation.  (Kuznetsov 
1997) and no markers are available to distinguish multipotent CFU-Fs from more 
committed  ones.  Nevertheless,  several  investigators  have  tried  different 
methods to enrich cultures for multipotent MSC. The most widely used approach 
employs monoclonal antibodies. One of the first antibodies shown to enrich for 
MSCs  is  the  Stro-1  antibody,  which  identifies  an  as  yet  uncharacterized  cell 
surface epitope expressed by MSCs and erythrocytic cells. (Gronthos 1994) Since 
other antigens such as  CD271 (low-affinity nerve growth factor receptor), CD18 
(b2  integrin)  or  the embryonic  stem  cell  marker  SSEA-4 have been  identified 
(Abdallah 2008). Enrichment of multipotent MSC has also been attempted by 
combining Stro-1 antibody with anti-CD106 (VCAM-1) or anti-CD146 (MUC18). 
(Abdallah 2008) However, sorting clonogenic progenitor by surface phenotype or 
sorting them by plastic adherence has the same pratical result (Sacchetti 2007).  
 
 
Figure  1:  the  diagram  depicts  the  plasticity  of  mesenchymal  stem  cells  and  their  capacity  to 
differentiate into different mature cells. From Caplan, 2007. ~ 4 ~ 
 
Bone marrow MSCs exert essentially two functions: - one is the classically 
recognized  function  of  providing  a  supporting  microenvironment  for 
hematopoiesis; - the other is related to the development and maintenance of the 
sinusoidal network. (Sacchetti 2007). Both HSCs and bone marrow MSCs localize 
to  the  sinusoidal  walls  of  bones  (Kiel  2006,  Sacchetti  2007),  and  when 
hematopoietic  development  is  modeled  in  vivo,  MSCs  do  so  prior  to  the 
establishment of hematopoiesis. (Sacchetti 2007).  MSCs secrete cytokines and 
growth factors that sustain HSCs maintenance and differentiation. Indeed, in the 
HSC niche, MSCs release a number of growth factors, such as stem cell factor 
(SCF),  interleukin(IL)-6,  lymphocyte  inhibitory  factor  and  granulocyte 
macrophage-colony stimulating factor (GM-CSF), but also negative regulators of 
hematopoiesis,  such  as  IL-8/CXCL8  and  transforming  growth  factor  (TGF-β). 
(Lazennec 2008) The interaction between HSCs and MSCs represents a unique, 
dual system of stem/progenitor cells that functionally interact in the regulation 
of hematopoiesis and bone physiology. 
The multipotency and secretory activity of MSCs make these stem cells an 
attractive target for cell based therapy. Furthermore, compelling evidence has 
shown the immunosuppressive properties of MSCs and their low immunogenic 
potential, allowing the use of allogeneic MSCs in therapeutic applications. (Le 
Blanc 2003, Bartholomew 2002) One approach takes advantage of MSC capacity 
to  differentiate  in  distinctive  mesenchymal  phenotype  to  tissue  engineering, 
encasing cells in tissue specific scaffolds and implanting into different tissue sites. 
For  example, MSCs  have  been  delivered to  long  bone repair  sites  in  calcium 
phosphate  porous  ceramics  to  produce  morphologically  and  biomechanically 
superior  bone.  (Petite  2000)  Likewise,  Solchaga  et  al.  used  hyaluronan  and 
polymeric  scaffolds  loaded  with  MSCs  for  cartilage  repair.  (Solchaga  2005)  A 
second therapeutic strategy uses transplantation of MSC in nonskeletal sites for 
the  repair  of  myocardium,  brain  and  more  (Barry  2003).  Indeed,  animal  or 
human MSCs have been used in animal models to affect heart infarct ischemia, 
stroke ischemia  and spinal cord interruption (Caplan 2007). Although evidence 
for the transplanted MSCs to transdifferentiate into nonmesodermal cell types 
has been controversial, the beneficial effects of transplantation may reside in the 
nursing effect conveyed by paracrine factors secreted by MSCs, that promote 
angiogenesis  and  stimulate  the  mitosis  of  tissue-intrinsic  stem  or  progenitor 
cells. (Caplan 2007) Another promising area of clinical application is the use of 
systemic  transplantation  of  MSCs  in  treatment  of  autoimmune  diseases, 
involving  their  immuneregulatory  effects.  For  example,  systemic  delivery  of ~ 5 ~ 
MSCs  has  been  tested  to  combat  graft  versus  host  disease  (GVHD)  during 
allogenic HSC transplantation and Crohn disease. (Ringden 2006, Caplan 2007).  
The  clinical  use  of  MSC  requires  a  better  understanding  of  the  regulatory 
pathways which control their self renewal and differentiation. 
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Retinoic acid (RA) is the biologically active naturally occurring member of 
a family of molecules called retinoids, all of which are derived from vitamin A. RA 
exerts specific control in embryonic development, regulating morphogenesis and 
organogenesis,  and  adult  tissue  cell  growth,  differentiation  and  apoptosis. 
(Chambon 1996, Altucci 2007) RA signaling is mediated by the activation of two 
ligand-activated nuclear transcription factors, the RA receptors (RARs) and the 
retinoid  X  receptors  (RXRs).  In  human,  rat  and  mouse,  there  are  three  RARs 
(RARα, RARβ and RARγ) and three RXRs (RXRα, RXRβ and RXRγ), that originate 
from six distinct genes. (Chambon 1996, Germain 2006(2)) RAR and RXR proteins 
share  a  common  organization  of  functional  domains:  an  amino  terminal  A/B 
region containing a transcriptional activation domain (AF-1), a centrally located C 
region corresponding to the DNA binding domain (DBD) plus a weak dimerization 
domain  and  the  E  region,  which  includes  the ligand  binding domain  (LBD),  a 
strong dimerization interface and a surface allowing binding of transcriptional 
coregulators.(Alvarez 2007) (Figure 2) For each RAR subtype, several isoforms 
exist that differ from one another in their N-terminal region A. These isoforms 
arise from the differential usage of two promoters and alternative splicing. The 
downstream promoters, referred to as P2, are induced by retinoids owing to the 
presence of a retinoic acid response element (RARE, see below) (Germain 2006).  
 ~ 6 ~ 
 
Figure 2: Structural organization and functional description of nuclear receptors commonly divided 
in modules A/B, C (DBD), D, E (LBD) and F. AD: activation domain. The structure of the ligand-
binding domain of hRAR
￿ bound to TTNPB is depicted. From Alvarez et al, 2007. 
 
The RARs and RXRs act as heterodimers (for example, RXRα–RARβ), and 
they recognize consensus sequences known as RAREs in the control elements of 
RA-responsive genes. In the absence of ligand, the RXR-RAR heterodimer recruits 
the corepressor proteins NCoR or SMRT and associated cofactors such as histone 
deacetylases (HDACs) or DNA-methyl transferases, that may lead to an inactive 
chromatin  structure,  preventing  transcription.  (Nagy  1997,  Privalsky  2001) 
Binding of RA to the RAR ligand binding pocket induces a conformational change 
of the LBD that creates a surface allowing the association of co-activators and 
the release of co-repressors. The co-activators (e.g. TIF2 and SRC-1 of the p160 
co-activator  family)  subsequently  mediate  histone  acetylation  resulting  in 
decondensation  of  the  chromatin  and  activation  of  target  gene  expression 
(Perissi 2005) (Figure 3). 
 ~ 7 ~ 
 
Figure 3: mechanism of RAR-RXR heterodimer activation. In the absence of the ligand, RAR-RXR 
heterodimer is associated with NCoR or SMRT corepressor complexes, that mediate chromatin 
condensation  and  transcription  repression.  The  binding  of  retinoic  acid  to  RAR  binding  pocket 
allows the exchange of corepressors for coactivators, such as CBP/p300 complex, which permits 
transcription  activation  by  mediating  histone  acetylation.  Modified  from  Perissi  and  Rosenfeld, 
2005. 
 
The different RAR subtypes exert diverse functions among various cell 
types.  For  instance,  RARγ  is  involved  in  maintenance  of  a  balance  between 
hematopoietic stem cell self-renewal and differentiation (Purton 2006). On the 
other hand, RARα is involved in the terminal differentiation of promyelocytes, 
and  the  altered  RARα,  PML-RARα  fusion  protein,  contributes  to  malignant 
transformation  in  acute  promyelocitic  leukemia  (APL)  by  mediating  an 
inappropriate repression of genes necessary for myeloid differentiation. Indeed, 
the PML fusion with RARα results in an enhanced recruitment of co-repressor 
HDAC  complexes  that  epigenetically  silence  gene  programmes. 
Supraphysiological  ATRA  levels  reestablish  the  normal  signaling  in  malignant 
cells, inducing RARα expression (Chomienne 1991) activating the differentiation 
program  and  tumour-selective  apoptosis.  (Chomienne  1989,  Altucci  2007) 
However, several other genes can form fusion protein with RARα, giving rise to 
ATRA-insensitive APL variants. The best known example is the PML zinc finger 
(PLZF)-RARα fusion protein: PLZF itself recruits the co-repressor HDAC complex, 
such that ligand-induced dissociation from the RARα moiety is insufficient for 
derepression and differentiation (Guidez 1994). The combination of ATRA with 
HDAC  inhibitor  like  VPA  can  restore  ATRA  sensitivity  in  ATRA-resistant  APL 
variants. (Grignani 1998) In addition, the combined therapy with HDAC inhibitor ~ 8 ~ 
and demethylating agents, such as 5-azacytidine (5-AZA), have been proposed to 
sensitize  AML  cells  to  the  effects  of  ATRA.  (Ferrara  2001,  Soriano  2007)  This 
therapeutic  effect  is  probably  due  to  the  induction  and  re-expression  of  the 
RARβ2 gene (Di Croce 2002) The RARβ2 isoform derives from the use of the 
ATRA-responsive promoter of RARβ gene, acting as a tumour suppressor. Indeed, 
RARβ2  is  frequently  lost  or  epigenetically  silenced  in  various  cancers  and, 
moreover,  its  expression  correlates  inversely  with  tumor  grade.  (Xu  2007) 
Furthermore, restoration of RARβ2 expression reactivates RA-dependent growth 
control. (Sirchia 2002) In contrast, RARβ4, another RA-inducible isoform of RARβ 
gene, seems to have oncogenic effects. In fact, RARβ4 was found to be increased 
in  esophageal  cancer  tissue  and  the  increase  was  associated  with  reduced 
expression  of  RARβ2.  (Xu  2005)  RARβ4  is  generating  from  the  same  RARβ2 
primary transcripts by alternative splicing, producing a much shorter A region –
only  4  amino  acid  long.  Because  RARβ4  protein  retains  the  ability  to 
heterodimerize with RXR and to interact with transcription cofactors but lack the 
DNA-binding  capacity  to  regulate  gene  expression,  it  may  act  as  a  dominant 
negative form of RARβ2. (Nagpal 1992) 
Explained by its crucial role in embryogenesis, it is expected that retinoic 
acid plays a central role also in pluripotent embryonic stem (ES) cell commitment 
and  differentiation.  It  is  largely  used  alone  or  in  combination  with  other 
differentiating factors to induce the terminal commitment of ES toward a specific 
cell lineage. For instance, treatment of ES cell-derived embryoid bodies with RA 
from day 0 to either day 2 or day 5 following embryoid body formation results in 
differentiation  of  ES  cells  to  neurons  and  glial  cells  (Soprano  2007)  Indeed, 
several lines of evidence demonstrate the role of RA in the perturbation of the 
genetic and epigenetic network that controls ES pluripotency and self-renewal. 
For  example,  Oct  4  expression,  a  POU  homeodomain  transcription  factor 
essential  for  ES  self-renewal  and  pluripotency,  is  repressed  by  RA-induced 
differentiation  by  both  a  deactivation  of  a  distal  upstream  stem  cell-specific 
enhancer and the silencing of its promoter (Okazawa 1991, Schoorlemmer 1993) 
Moreover,  microRNAs  (miRNA),  a  class  of  short  RNAs  mediating  sequence-
specific  post-transcriptional  repression  of  target  transcript,  targeting  Oct4, 
Nanog and Sox2 mRNA are upregulated during RA treatment of mouse ES cells, 
modulating  their  differentiation  (Tay  2008)  Indeed,  Oct-4,  Sox2  and  Nanog 
proteins are essential transcription factors that operate coordinately to maintain 
ES  pluripotency  by  both  activation  of  downstream  self-renewal  genes  and 
repression of differentiation-promoting genes. (Boyer 2005, Loh 2006) In fact, 
they  establish  a  complex  genetic  network  by  a  reciprocal  regulation  of  each ~ 9 ~ 
other’s  expression  and  the  induction  of  downstream  genes  important  for  ES 
maintenance and self-renewal, such as Tcl1 and Sall4. (Loh 2008) In addition, the 
overexpression of a defined group of transcription factors (e.g. Oct4, Sox2, Klf4 
and c-Myc) is sufficient to reestablish a pluripotent state in mouse embryonic 
fibroblast. (Yamanaka 2006) This genetic network is also interconnected with 
epigenetic regulation of chromatin structure. (Figure 4) In fact, it has been shown 
that Oct4, Sox2 and Nanog co-regulates certain genes encoding components of 
chromatin remodeling and histone modifying complexes (Boyer 2005), and they 
can interact directly or indirectly with them (Wang 2006). In addition, Polycomb 
group proteins (PcG), a well-known group of factors involved in the silencing of 
developmental  regulators,  co-occupy  a  significant  fraction  of  Oct4,  Sox2  and 
Nanog  regulated  genes,  raising the possibility  that these transcription factors 
recruit PcG proteins to their target sites. (Lee 2006) 
 
 
Figure 4: interplay between genetic and epigenetic factors in regulation of pluripotency in ES cells. 
The pluripotency transcription factors  (e.g. Oct4, Sox2 and Nanog) act both in the activation of 
downstream genes involved in stemcellness maintenance and self-renewal and in the repression of 
developmental genes. Epigenetic regulators, such as PcG proteins and histone modifying factors, 
cooperate with genetic factors to the regulation of the gene expression programmes. Differentiating 
stimuli, such as retinoic acid treatment, downregulate the expression level of pluripotency factors by 
different mechanism (e.g., miRNA) and induce the expression of developmental genes. From Chen 
and Daley, 2008. 
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The aim of this project is to study the effects of in vitro treatment of 
epigenetic  and  differentiation  modifying  drugs  (all-trans  retinoic  acid  (ATRA) 
alone or in combination with 5-azacytidine and valproic acid) in mesenchymal 
stem cells derived from healthy donors and leukemic patients. We first evaluated 
the effects on the biological properties of MSCs, such as proliferation, apoptosis, 
senescence and differentiation potential. We then focused on the RA signaling 
pathways in MSC cells by, assessing the level of expression of  the three RARs ~ 10 ~ 
and RXRs after ATRA treatment. Finally, we investigated the effect of ATRA on 
the expression of genes known to be involved in embryonic and adult stem cell 
self-renewal and multipotency, such as Oct4, Sox2 and Nanog.  
The long term goal of the project is to evaluate the effect of ATRA, AZA 
and VPA either alone or in combination in MSCs, due to their potential clinical 
application in regenerative medicine and their intimate role in regulating HSC 
self-renewal and differentiation. This could lead to a better understanding of the 
mechanism  of  action  and  side  effects  of  these  three  drugs  in  the  cure  of 
hematological malignancies. ~ 11 ~ 
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MSCs were isolated from bone marrow samples obtained from 7 healthy 
donor and 2 AML patients after informed consent was obtained. Bone marrow 
samples were diluted with one third vol/vol of PBS+EDTA (2mM EDTA) and posed 
in  a  layer  of  Ficoll  of  density  of  1.073  g/mL  (Invitrogen).  The  cells  were 
centrifuged  at  1.100  RPM  for  30  minutes  at  4 
oC.  Mononuclear  cells  were 
collected  from  Ficoll  layer  and  washed  twice  with  PBS+EDTA.  Cell  pellet  was 
suspended  in  stem  cell  medium  consisting  of  α-modified  Eagle’s  Medium 
(αMEM, Invitrogen) containing 10% of Fetal Calf Serum (FCS, Hyclone), 1 ng/mL 
basic  FGF  (R&D),  1%  (vol/vol)  GlutaMAX  (Invitrogen),  and  a  combination  of 
antibiotics/antimycotics. Cells were plated at a density of 5x10
3 cells/cm
2. After 
24-48 hours at 37 
oC with 5% of CO2 pression, non-adherent cells were discarded 
and the culture medium was changed. Medium was changed every 2-3 days until 
cells  reached  confluence:  they  were  detached  with  trypsin  and  seeded  at  a 
density of 5000 cells/cm
2 for propagation. 
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MSCs were detached with trypsin and resuspended in PBS. 1x10
5 cells 
were incubated at 4 
oC for 15 minutes in presence of a set of different antibodies 
diluted 1 to 20. Antibodies used are coupled with -Fluorescein isothiocyanate 
(FITC) or –Phycoerythrin (PE). Cells were then washed with PBS and analyzed by 
FACS. Isotypic antibodies coupled with the appropriated fluorochrome were used 
as negative controls. 
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Cells were plated in stem cell medium at a density of 5.000 cells/cm
2. 
After  24-48  hours  the  medium  was  removed  and  changed  with  medium 
contained  different  concentration  of  all-trans  retinoic  acid  (ATRA,  Sigma),  5-
azacytidine  (AZA,  Sigma),  valproic  acid  (VPA,  Sigma),  RARβ2  isoform  specific 
agonist  AC55649  (Tocris  Bioscience)  (Piu  2005)  and/or  RARβ  subtype  specific ~ 12 ~ 
antagonist LE135 (Tocris Bioscience) (Li 1999). Stock solutions of ATRA, LE135 
and AC55649 was made by addition of DMSO (1 mM for LE135 and AC55649, 0,1 
mM for ATRA). AZA was diluted with PBS at a concentration of 1 mM, instead 
VPA  was  resuspended  in  distilled  water  at  a  concentration  of  1  M.  All  stock 
solutions were stored at -80
oC. The medium was changed every 2-3 days and 
cells were collected at the specified time. All experiments were carried out on 
cells from passage 2 to 5. 
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Before inducing adipogenic differentiation, cultured cells were seeded in 
175 cm² flask (BD) at a density of 5000 cells/cm² in basal medium added with 1 
µM ATRA, AC55649, LE135 or both ATRA and LE135. After one week cells were 
detached and plated in 6-well plates at 70-80% of confluence. After 24 hours 
medium was replaced with adipogenic medium consisting of Dulbecco’s modified 
Eagles Medium (DMEM, Invitrogen) supplemented with 1 g/L of glucose, 20% of 
FBS,  0.5  mM  3-isobuthyl-1-methylxantine  (Sigma),  60  µM  indomethacine 
(Sigma), 1 µM dexamethasone (Merk) and 5 µg/mL insulin in presence of ATRA 
and RARβ agonist or antagonist. The medium was replaced every 3-4 days, and 
after  14  days  of  culture  the  presence  of  cells  containing  lipidic  vesicles  was 
observed and quantified by Nile red staining. Cells were discarded with trypsin 
and washed twice with PBS. They were then suspended in PBS in a total volume 
of 400 µL and fixed by the addition of 40 µL of 4% paraformaldehyde. After 
washing with PBS, cells were stained with the addition of 500 µL of a solution 
containing 1 µg/mL of Nile red dye on ice for 30 minutes. The samples were then 
analyzed with a flow cytometer. Nile red fluorescence emission was measured on 
the FL2 emission channel through a 585±21 nm band pass filter, after excitation 
with an argon ion laser source at 488 nm.  
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MSCs were first cultivated in 175 cm² flask (BD) at a density of 5x10
3 
cells/cm
2 in stem cell medium supplemented with 1 µM ATRA, AC55649, LE135 
or both ATRA and LE135. After 7 days of culture cells were detached and seeded 
in 6-well plates at 70-80% of confluence. Osteogenic differentiation was induced 
by the addition of osteogenic medium composed of DMEM (Invitrogen) supplied 
with 4.5 g/L glucose, 10% of FBS, 10
-7 M dexamethasone, 50 µg/mL ascorbic acid 
and  3  mM  inorganic  phosphate  in  presence  of  1  µM  ATRA,  RARβ  agonist  or 
antagonist.  The  medium  was  changed  twice  per  week  and  after  14  days  of ~ 13 ~ 
treatment osteogenesis was quantified by alkaline phosphatase activity and after 
21 days of treatment the mineralization of extracellular matrix was evaluated by 
the coloration with Alizarin Red.  
For  the  quantification  of  ALP  activity  cells  were  lysed  with  a  HNT 
(Hepes/NaCl/Triton) tampon solution and centrifuged at 300 g at 4 
oC for 10 
minutes. The supernatant was placed in a 96-well plate with an equal volume of 
reaction  solution  (Biorad  Alkaline  Phosphatase  substrate  kit,  Biorad)  and 
incubated at 37 
oC. The reaction was stopped when a yellow coloration appeared 
by adding a solution of 0.4 M NaOH and optical density was read at 405 nm using 
a  96-well  plate  reader.  Absorption  values  were  then  normalized  to  nmol  of 
produced  nitrophenol/minutes  of  incubation/total  protein  content  for 
standardization. The experiment was carried out in duplicate for each condition 
tested. 
The  coloration  with  Alizarin  Red  evaluated  the  mineralization  of  the 
extracellular  matrix  produced  by  osteoblasts.  Cells  were  fixed  with  10% 
formaldehyde at room temperature for 15 minutes. Then cells were rinsed three 
times with distilled water and stained with 1 mL of staining solution containing 
40  mM  Alizarin  Red  at  room  temperature  for  20  minutes  with  shaking.  The 
excess  of  dye  was  removed  and  cells  were  washed  four  times  with  distilled 
water. We added 800 µL of 10% acetic acid to each well and incubated for 30 
minutes with shaking. Cellular monolayer was then scrapped with the aid of a 
cell  scraper  and  cells  and  acetic  acid  were  transferred  to  a  1.5  mL 
microcentrifuge  tube.  The  solution  was  heated  at  85 
oC  for  10  minutes  and 
cooled on ice for 5 minutes. We then centrifuged the solution at 20.000 g for 15 
minutes  and the  supernatant  was  transferred in  a  new  tube.  200  µL of  10% 
ammonium hydroxide was added to neutralize the pH and read the absorbance 
at 405 nm using a 96-well plate reader. The quantification of Alizarin Red staining 
was performed using a calibration curve of known concentrations of the dye. The 
experiment was carried out in duplicate for each condition tested. 
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Mononuclear cells isolated from Ficoll layer were washed twice with PBS 
and resuspended in stem cell medium. Cells were plated in 6-well plate at 3 
different densities in duplicate: 40.000 cells/cm
2, 20.000 cells/cm
2 and 10.000 
cells/cm
2. After 24-48 hours non-adherent cells were discarded and medium was ~ 14 ~ 
changed with fresh medium containing 1 µM ATRA, 1 µM AZA, 1 mM VPA, either 
alone or in combination. The medium was changed every 3-4 days and at day 14 
cells were collected for colony staining with Giemsa (Biolyon, Oxoid). Cells were 
fixed with methanol (Merck Eurolab) for 10 minutes at 25 
oC and rinsed twice 
with PBS. Fixed cells were incubated with Giemsa staining solution for 5 minutes 
and  then  washed  twice  with  PBS  to  remove  additional  staining.  We  counted 
fibroblastic colonies under light microscope.  
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Cells were seeded in 10 cm
2 plates at 5x10
3 cells per cm
2 density in stem 
cell medium. After 24 hours the medium were replaced with the fresh medium 
containing 1 µM ATRA, 1 µM AZA, 1mM of VPA, 1 µM AC55649, 1 µM LE135 or 
combinations of drugs at the concentrations previously indicated. The medium 
was changed after 48 hours, and cells were collected at 5 days after treatment. 
Cells were detached with trypsin and washed twice with PBS by centrifugation. 
Apoptotic cells were detected with FITC Annexin V Apoptosis Detection Kit II (BD 
Pharmigen), according to the manufacturer’s protocol. Briefly, PBS was removed 
and the cell pellet was resuspended with 100 µL of Annexin V Binding Buffer, 20 
µL of 7-Amino-Actinomycin (7-AAD) and 5 µL of FITC Annexin V solution. Cells 
were incubated for 10 minutes at 4 
oC in the dark, and then we added 400 µL of 
binding  solution.  The  analysis  of  apoptotic  cells  were  performed  by  flow 
cytometry.  
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We plated 30.000 cells per wells in 6-wells plate in culture medium to 
permit cells to adhere. After 24 hours the medium were replaced with fresh 
medium containing the concentration of drugs indicated before. At day 2 the 
medium was changed and MSCs were treated with 10μM bromodeoxyuridine 
(BrdU) for 24 h and assayed according to the protocol of BrdU flow kits (BD 
Pharmingen, San Diego, CA,) using flow cytometry. Briefly, cells were first fixed 
and  permeabilized  with  BD  Cytofix/Cytoperm  Buffer,  treated  with  DNase  to 
expose incorporated BrdU (30µg of DNase to for each sample) and stained with 
FITC-conjugated  anti-BrdU  antibodies  and  7-AAD.  Stained  cells  were  then 
analyzed with a flow cytometer. ~ 15 ~ 
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For the proliferation test we plated 500 cells/well in 96-well plate in stem 
cells medium. After 24-48 hours the medium was replaced with fresh medium 
containing serial dilutions of ATRA, AZA, VPA, AC55649 and LE135 alone (0.5, 1, 2 
µM for ATRA and AZA, 0.5, 1 and 2 mM for VPA, 1 µM for AC55649, 1 µM for 
LE135) or combination of drugs (1 µM for ATRA, AZA and LE135, 1 mM for VPA). 
The medium was changed at day 2 and 5 after starting the treatment, and viable 
cell number was determined at day 2, 5 and 8. The determination of cell number 
was  performed  by  using  CellTiter  96  Non-Radioactive  Cell  Proliferation  Assay 
(Promega),  following  the  manufacturer’s  instructions.  The  CellTiter  Assay  is 
based on the cellular conversion of a tetrazolium salt into a formazan product 
that is detected using a 96-well plate reader, providing an indirect measure of 
viable cell number by measuring metabolic activity of cellular enzymes. At day of 
testing culture medium was removed and cells were washed with PBS. Cells were 
incubated with 100 µL of PBS and 20 µL of Dye solution at 37 
oC. The absorbance 
was recorded at 570 nm after 2 hours of incubation using a 96-well plate reader. 
￿
￿
￿
￿
￿
"
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
 
￿
￿
#
￿
￿
￿
￿
￿
￿
￿
￿
 
￿
￿
￿
￿
￿
￿
￿
￿
MSCs  were  seeded  in  12-well  plate  at  a  density  of  5.000  cells/cm
2  in 
culture medium. After 24-48 hours the medium was replaced with fresh medium 
supplemented with 1 µM ATRA, 1 µM AZA, 1 mM VPA or combination of the 
three  drugs  as  previously  described.  Medium  was  changed  after  2  days  of 
treatment  and  senescence  assay  was  performed  at  day  5.  The  detection  of 
senescent cells were carried out using the Senescence β-Galactosidase Staining 
Kit  (Cell  Signaling  Technology),  which  histochemically  detects  β-galactosidase 
activity at ph 6, according to the manufacturer’s instructions. Briefly, cells were 
washed  with  PBS  and  fixed  with  Fixative  solution  for  15  minutes  at  room 
temperature. Next we added 1 mL of Staining Solution mix (containing 1 µg/mL 
5-bromo-4-chloro-3-indolyl-beta-D-galactopiranoside) to the plate and incubated 
overnight at 37 
oC. Plates were observed under light microscope to recognize the 
development of blue color in senescent cells. 
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Cultured MSCs were plated in 25 cm
2 flasks at a density of 8.000 cells/cm
2 
in basal medium. After 3-4 days of culture we started the treatment by adding 1 ~ 16 ~ 
µM ATRA to stem cell medium. Cells were collected at 0.5, 1, 2, 4, 8, 24, 48, 72 
and 120 hours after the beginning of the treatment, depending on experimental 
design. For CFU-F RNA extraction, mononuclear cells isolated from Ficoll were 
seeded in 75 cm² flasks at a density of 5000 cells/cm² in basal medium. After 24 
hours  medium  was  replaced  with  fresh  ones  with  or  without  1  µM  ATRA. 
Medium was changed every 2-3 days and cells were collected after 14 days of 
treatment. Cell pellets was stored at -20 
oC. 
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Total RNA was extracted by cell pellet using RNeasy Mini Kit (Qiagen), 
following the manufacturer’s instructions. The content of RNA of each sample 
was  quantified  using  Nanodrop  2000  spectrophotometer  (Thermo  Scientific). 
First-strand  cDNA  was  synthesized  using  High  Capacity  cDNA  Reverse 
Transcription Kit (Applied Biosystem), following the manufacturer’s instructions. 
Total  RNA  (500  ng)  was  reverse-transcribed  in  a  20  µL  reaction  volume 
containing MgCl2 (5 mM), PCR BufferII (1X), RNase inhibitor (1U/µL), Multiscribe 
Reverse Transcriptase (50 U), random primers (2.5 µM) and dNTPs (1 mM each). 
The tubes were placed in the thermal cycler at 25 
oC for 10 minutes, 37 
oC for 2 
hours and 85 
oC for 5 seconds. We added 60 µL of RNase-free water to each tube 
at the end of the reverse transcription reaction. 
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Quantitative real-time polymerase chain reaction was performed in a 25-
µL reaction consisting of 12.5 µL of TaqMan Universal PCR Master Mix (Qiagen), 
2.5 µL of the RT reaction, and 600 nM primers using 7500 Fast Real-Time PCR 
System  (Applied  Biosystem).  The  amplification  program  consisted  of  initial 
denaturation at 95 
oC for 10 minutes, followed by 40 cycles of denaturation at 95 
oC for 15 seconds and annealing/extension at 60 
oC for 1 minute, and finally 7 
minutes at 72 
oC. Real-time PCR assays were performed in duplicate or triplicate 
for each MSC tested. We measured the cycle threshold (Ct) value for each gene 
of interest. The Ct value of porphobilinogen deaminase (PBGD) gene was used as 
an  internal  reference  for  normalization.  Specific  primers  for  RAR  and  RXR 
receptors and for self renewal genes were purchased from Applied Biosystem 
(TaqMan  Gene  Expression  Assays,  Applied  Biosystem;  proprietary  primers, 
sequence not disclosed). Primers for PBGD and RARβ2 isoform were purchased 
from Sigma Proligo, and primers for RARβ4 isoform were synthesized by Eurofins 
MWG Operon. The sequence of primers used was as follow: RARβ2 (forward, F) ~ 17 ~ 
5’-CTAAATACACCACGAATTCCAGTGCTGA-3’,  RARβ2  (reverse,  R)  5’-
CAGACGTTTAGCAAACTCCACGATCTTA-3’;  RARβ4  (F)  5’-
TTGGAAGGAGAACTTGGGATC-3’,  (R)  5’-TCAATTGCATTTTCCAGGCT-3’;  PBGD  (F) 
5’-GGAGCCATGTCTGGTAACGGCA-3’, (R) 5’-GGTACCCACGCGAATCACTCTCA-3’. 
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Comparison  in  the  difference  of  all  data  presented  between  paired 
sample was by one-tailed paired t test using GraphPad Prism software (GraphPad 
Prism version 5.0 for Windows, GraphPad Software, San Diego, CA). In all tests, 
p<0.05 was taken as significant. ~ 18 ~ 
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Mesenchymal stem cells were first isolated from bone marrow for their 
ability to form colony of fibroblastic cells (CFU-F) when plated at clonal density 
(Friedenstein  1966)  To  first  investigate  the  effects  of  ATRA,  AZA  and  VPA  in 
MSCs, the action of the different treatments was evaluated on the formation of 
colonies in mononuclear cells isolated from normal bone marrow aspirates by 
density gradient. 
Samples derived from different donors showed a variation in the number 
of CFU-Fs, probably due to an intrinsic variability of the number of the MSCs in 
bone marrow aspirates and to isolation process. Treatment of cells with 1 µM 
ATRA, 1 µM AZA, 1 mM VPA or a combination of AZA and VPA or of the three 
drugs  reduced  the  number  of  colonies  present  in  the  plate  (3.92  colony/10
5 
mononuclear cells for untreated samples (UNT) compared to 2.62 ATRA, 2.45 
AZA,  1.46  VPA,  1.15  AZA+VPA  and  0.25  AVA  treated  samples  (Fig.  5).  This 
inhibition  is  statistically  significant  compared  to  untreated  cells  for  all  the 
treatments (p<0,05). The combination of the three drugs (AVA) showed a greater 
inhibitory effect on the CFU-F count, maybe due to a cooperation of drugs. In 
addition,  the  treatment  with  AZA  and  VPA  alone  or  in  combination  reduced 
colony  size  and  density,  and  changed  the  morphology  of  cells  (Fig.  6  D-G). 
Indeed,  cells  appeared  larger  and  more  flattened:  probably  linked  to  their 
commitment  toward  a  non-proliferative  or  differentiated  status.  In  contrast, 
ATRA treatment showed a more variable effect on CFU-F formation: in the same 
well there were colonies with marked changes in cell morphology and others 
with no visible alteration compared to untreated cells (Fig. 6 B-C). 
 ~ 19 ~ 
 
Figure 5:  CFU-F number. The number of colonies is expressed as  CFU-F/10
5 mononuclear cells. 
Data represent the mean of 6 independent experiment ±sem. 
 
 
 
Figure 6: Microscopical aspect of untreated (A) and treated (B-H) cells. (400x). ATRA-treated CFU-
Fs present both spindle-shaped (B) and flattened (C) morphology. Cells exposed to AZA (D), VPA 
(E), combination of AZA and VPA (F) or all the three drugs (G) undergo a drastic changing in cell 
shape and a reduction of colony density. 
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To further characterize the effect of the three drugs on MSCs, cells were 
isolated by their ability to adhere to the plastic surface and then characterized by 
flow  cytometry  analysis  to  confirm  the  absence  of  contamination  of 
hematopoietic  and  endothelial  cells.  The  proliferation  rate  of  cultured  MSCs 
were then tested by an MTS assay. Viable cell number was determined after 2, 5 
and 8 days of treatment with different concentrations of ATRA, AZA and VPA, 
either  alone  or  in  combination.  For  treatment  with  ATRA,  control  cells  were 
cultured with an equal amount of DMSO.  
The presence of ATRA in the culture medium enhances the proliferation 
of MSCs after 5 and 8 days of culture compared to cells exposed to the same 
amount of DMSO (p-value<0.05) and untreated cells, even if in this case the 
differences are not statistically significant (Fig. 7A). No concentration-dependent 
effect was found for ATRA treatment at the concentrations tested. In contrast, 
treatment of MSCs with AZA and VPA alone or in combination decreases the 
proliferation of MSCs compared to control cells after 5 and 8 days of treatment 
(p-value<0.05), as it was shown for CFU-F assay. VPA presents a concentration-
dependent inhibition on proliferation 5 days after treatment and AZA after 8 
days(Fig. 7 B-C). The combination of AZA and VPA has a cooperative inhibitory 
effect compared to AZA 1µM and VPA 1mM after 8 days(p-value<0.05) (Fig. 7B). 
The addition of ATRA to AZA+VPA treated cells attenuated the phenotype due to 
the two epigenetic drugs, confirming its role in promoting MSC proliferation (Fig. 
7B). 
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Figure 7:Results on MSC proliferation assessed by the MTS test on ATRA (A), VPA (B) and AZA 
(C) treated MSCs. (A) The treatment with ATRA promotes the proliferation of cultured MSCs; (B-C) 
in contrast, both AZA and VPA treatments show a concentration-dependent reduction of viable cells 
after 5 and 8 days of culture. Data represent the mean of three independent experiments ±sem. 
Each experiment was done in triplicate. 
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The decrease of viable cells by AZA and VPA may be due to an induction 
of  apoptosis  or  senescence  in  MSC  culture.  To  test  this  hypothesis,  we  first 
evaluate the rate of apoptotic cells in the presence of the three drugs. Figure 8 
shows  the  data  collected  after  5  days  by  flow  cytometry  with  Annexin 
V/propidium iodide two color staining. Surprisingly, treatment with ATRA seems 
to enhance the percentage of apoptotic cells compared to control cells (1.82% 
UNT compared to 3.07% in ATRA treated cells), even if this difference has no 
statistical  meaning  and  the  numbers  are  very  low  (Fig.  8  A).  AZA  and  VPA 
C 
B ~ 22 ~ 
treatments increase the number of apoptotic cells compared to untreated cells 
(2.03% and 4,95% respectively), but the results are not significantly different (Fig. 
8 B). The combinations AZA+VPA and AVA trigger the most striking effect on 
cultured  MSCs  viability,  and  this  increase  of  apoptotic  cells  is  statistically 
significant compared to untreated cells and single treatment (p-value<0.05) (Fig. 
8 B). Moreover, the addition of ATRA to the combination of the two epigenetic 
drugs  enhances  apoptosis  (7.96%  for  AZA+VPA  compared  to  11.39%  for  AVA 
treatment), but this increase is not statistically important. 
 
 
 
Figure 8: Effect on apoptosis. (A) The addition of ATRA in culture medium increases the number of 
apoptotic cells. (B) Both AZA and VPA treatments enhance apoptosis of cultured MSCS, but the 
differences are significant only for the combination of treatment compared to untreated and single 
treated cells (p-value<0.05%). Data represent the mean ±sem of four independent experiments. 
 
The flattened morphology of cells in CFU-F is a typical indicator of the 
presence  of  suffering  and  non-proliferative  cells  in  the  culture.  We  thus 
evaluated  the  presence  of  senescence  in  control  and  treated  cells  by  the 
recognition of β-galactosidase activity, a well-known marker of senescent cells, 
after  5  days  of  culture.  As  it  is  shown  in  Figure  9,  no  senescent  cells  were 
detected  in  all  conditions  tested.  In  addition,  treatments  with  AZA  and  VPA 
either alone or in combination cause modifications of cell shape very similar to 
those observed for treated CFU-F (Fig. 9 C-E; Fig. 6 D-G). On the other hand, 
exposure to  ATRA seems not to affect cell morphology of cultured MSCs (Fig. 9B) 
This  finding  is  consistent  with  enhancement  of  proliferation  in  ATRA-treated 
MSCs, and it may explain the opposite effects of the drug between CFU-F and 
cultured MSCs. 
 
A  B ~ 23 ~ 
 
Figure 9: Detection of 
￿-galactosidase activity after 5 days of culture. No blue cells were detected in 
all condition tested. Cells treated with ATRA (B) show no difference in cell morphology compared to 
control (A). In contrast, cells treated with AZA (C), VPA (D) or combination (E, AZA+VPA; F, AVA) 
appear flattened and planar. Images were taken with 400X magnification under light microscope. 
 
Our data suggest that AZA and VPA treatments reduce the number of 
CFU-F and viable MSCs by the induction of apoptosis and a commitment of cells 
toward a less proliferative state. In contrast, ATRA seems to act in opposite ways 
in earlier progenitor cells (i.e., CFU-Fs) compared to cultured MSCs.  
We thus focus on the treatment with ATRA to unravel the reason for the 
differing behavior of CFU-F and cultured MSCs. 
 
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
 
To  confirm  the  effect  of  ATRA  treatment  on  MSC  proliferation,  the 
distribution  along  cell  cycle  phases  was  verified  by  the  incorporation  of  5-
Bromodeoxyuridine (BrdU). After 3 days of culture, cells treated with ATRA show 
a comparable percentage of cells in sub-G1 and G1 phases (2.08% and 37.56% in 
ATRA-treated cells against 2.26% and 37.88 % of untreated cells)(Fig. 10 A-B). ~ 24 ~ 
Surprisingly, the presence of ATRA reduced significantly the fraction of cells in M 
phase of cell cycle division compared to control cells (3.20% in treated cells and 
5.50%  for  controls,  p<0.01),  but  it  increases  the  number  of  cell  in  S  phase 
(57.15% for ATRA and 54.36% for control cells) (Fig. 10 C-D). These data suggest 
that ATRA treatment does not select a subpopulation in cultured MSCs, as no 
significant increase of the percentage of cells in active division was seen. On the 
other hand, this did not explain why ATRA enhances the number of viable cells, 
as it seems not to influence the division rate of cultured MSCs. 
 
 
 
Figure 10: Analysis of distribution of cells along cell cycle phases.(A-B) No difference was found 
between control and treated cells in the percentage of sub-G1 and G1 cells after 3 days of culture. A 
tiny increase of s cells was seen in cell treated with ATRA (C), at which corresponds an equal 
reduction  of  G2-M  cells  compared  to  controls  (D).  Data  represent  the  mean  ±sem  of  three 
independent experiments. 
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Retinoic acid signaling is mediated by the binding to and activation of RAR 
and RXR receptors, which are also induced by the RA treatment through the 
A  B 
C  D ~ 25 ~ 
presence  of  a  RARE  in  their  promoter  region.  To  determine  which  receptors 
mediates ATRA signaling in MSCs, we assessed the basal expression level of the 
receptors and the variation induced by ATRA. 
As it is shown in Figure 11, all RARs and RXRs are expressed in both CFU-F 
and MSCs, except for RXRγ. CFU-Fs express levels of RXRα and RXRβ drastically 
lower compared to cultured MSCs, and the differences are statistically significant 
(p<0.05 for RXRα, p<0.01 for RXRβ). Also RARγ expression is reduced in CFU-F 
compared to MSCs (0,52 and 1.30, respectively), instead RARα seems to be more 
expressed (3.11 in CFU-F compared to 1.76 in cultured MSCs). Differences in RAR 
and  RXR  expression  level  may  explain  the  opposite  effect  of  retinoic  acid 
treatment in CFU-F and cultured MSCs. 
 
 
Figure 11: basal level of expression of RARs and RXRs in CFU-F (A) and cultured MSC (B). The 
value were normalized compared to the expression of the housekeeping gene PBGD. The data 
show the mean ±sem of three independent experiments. 
 
The  presence  of  ATRA  in  the  medium  alters  in  a  similar  way  the 
expression profile of retinoic acid receptors in both CFU-Fs and MSCs. In fact, a 
remarkable increase in RARβ expression is induced by ATRA compared to control 
cells  (Fig.  12  A-C),  with  no  relevant  variation  in  the  expression  of  the  other 
receptors (Fig 12 A-B, D-F). In cultured MSCs, the induction of RARβ starts after 2 
hours of treatment, reaching a peak at 8 hours and it stabilizes 24 hours after 
treatment (Fig. 12 C). 
 
A  B ~ 26 ~ 
 
 
Figure 12: expression fold change of RAR and RXR receptors after addition of ATRA. mRNA levels 
of RAR
￿ are notably enhance by ATRA treatment in both CFU-F (A) and cultured MSCs (C). No 
significant differences were seen in the expression of other retinoic acid receptors (A-B, D-F). For 
cultured MSCs the expression levels of the receptor were analyzed after 0.5, 1, 2, 4, 8 and 24 
hours of treatment. Values are normalized to the expression of control cells collected at the same 
timepoint. The data shown the mean ±sem of three independent experiments. 
 
The RARβ receptor presents two RA-induced isoforms, RARβ2 and RARβ4, 
that  differ  for  their  N-terminal  region  A,  which  contains  the  transcriptional 
activation domain AF-1. Indeed, the RARβ2 isoform acts as a tumor suppressor in 
different  types  of  cancers  and  its  expression  correlates  inversely  with  tumor 
grade (Xu 2007). In contrast, the RARβ4 isoform seems to have an oncogenic 
effect, because its expression is increased in esophageal cancer tissue and this 
correlates with reduced expression of RARβ2 isoform (Xu 2005). We evaluated 
A 
C 
B 
D 
E  F ~ 27 ~ 
the mRNA level of the two isoform and the presence of variation after ATRA 
treatment  in  cultured  MSCs.  Figure  13  shows  the  ratio  between  RARβ2  and 
RARβ4 mRNA transcript level after 8 and 24 hours of treatment. No notable 
discrepancies are observed between control and untreated cells. In fact, the two 
isoforms arise from the same promoter, and they share the same regulation by 
ATRA.  RARβ2  transcript  is  50-60  times  more  expressed  than  the  β4  isoform, 
suggesting that RARβ2 mediates the effect of ATRA treatment in cultured MSCs. 
To  test  this  hypothesis,  we  verify  the  effect  of  a  RARβ2  specific  agonist 
(AC55649) (Piu 2005) and a RARβ selective antagonist (LE135) (Li 1999) in the 
proliferation and apoptosis of cultured MSCs. 
 
 
Figure 13: Ratio of RAR 
￿2/
￿4 isoforms in cultured MSCs after 8 and 24 hours of treatment. No 
significant  difference  is  present  compared  to  control  cells.  Data  show  the  mean  ±sem  of  four 
independent experiments. 
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To control the involvement of RARβ2 isoform in mediating ATRA signaling 
we took advantage of  a RARβ2-selective agonist, AC55649, and a RARβ-specific 
antagonist, LE135, at the same concentration of ATRA. 
The addition of AC55649 to the medium enhances the number of viable 
cells compared to untreated cells and cells treated with the same amount of 
DMSO after 5 and 8 days of culture (Fig. 14 A), even if the differences are not 
statistically significant. However, with the RARβ2 agonist  the stimulating effect is 
similar to equal concentration of ATRA (Fig. 14 A). On the other hand, LE135 
mediates a tiny increase of viable cells compared with untreated cells and DMSO 
control  cells,  but  its  effect  notably  differs  from  ATRA  (p-value<0.05).  The 
concurrent  treatment  with  ATRA  and  RARβ  antagonist  reduces  the  effect  of 
ATRA alone, even if the differences is not statistically significant (Fig. 14 A).  ~ 28 ~ 
The quantification of the percentage of apoptotic cells after 5 days of 
treatment confirms the role of RARβ2 in mediating ATRA signaling. In fact, the 
treatment with AG55649 increases the number of apoptotic cells compared to 
controls (2.21% and 1.82%, respectively), even if the difference is not statistically 
relevant (Fig. 14 B). Moreover, the presence of LE135 in the medium reduces 
significantly the number of apoptotic cells compared to untreated (p<0.01) and 
AC55649-treated cells (p<0.05), but this reduction is not statistical appreciable 
compared to ATRA treatment (1.37% for LE135 and 3.07% for ATRA) (Fig. 14 B). 
This protective effect of LE135 treatment might explain the small increase of 
viable cells compared to cells treated with the same amount of DMSO seen in 
proliferation  test.  Finally,  the  addition  of  both  ATRA  and  RARβ  antagonist  in 
culture medium diminishes the percentage of apoptotic cells compared to ATRA 
alone (2.28% for ATRA+LE135) (Fig. 14 B). 
 
 
A ~ 29 ~ 
 
Figure 14: MTS (A) and percentage of apoptotic cells (B) in cells treated with ATRA, RAR
￿ agonist 
(AC55649) and RAR
￿ antagonist (LE135). AC55649 mediates the same effect on cell proliferation 
and apoptosis than ATRA, even if in a more attenuate fashion. In contrast, LE135 protects cells 
from apoptosis compared both to untreated and treated cells. The addition of RAR
￿ antagonist to 
ATRA treatment reduces the proliferative and proapoptotic effect of ATRA. Data represents the 
mean ±sem of three (A) or four (B) independent experiments. 
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Retinoids are known for their effects on cell growth and differentiation in 
embryogenesis and adult tissues. Thus the treatment with ATRA could influence 
the multipotency of MSCs by priming them towards a specific cellular lineage. To 
address  this  question,  we  evaluated  the  effect  of  ATRA,  RARβ  agonist  and 
antagonist before or during adipogenic and osteogenic differentiation of cultured 
MSCs.  
Figure 15 shows the data for the adipogenic differentiation, revealed by 
the staining of lipid droplets in cytoplasm of adipocyte with Nile Red dye. All the 
treatments seem to enhance the percentage of differentiated cells compared to 
untreated cells(Fig. 15 A), even if this difference is statistically significant only for 
ATRA (p<0.05). In addition, the treatment of cells with ATRA and AC55649 before 
inducing differentiation doesn’t prime MSCs toward the adipocytic lineage (Fig. 
15 B). In contrast, LE135 pretreatment seems to decrease the number of Nile 
Red positive cells: indeed it has been described that this compound can drive 
MSCs to the chondrogenic pathway (Kafienah 2007). 
 
B ~ 30 ~ 
 
Figure  15:  Nile  red  staining  of  cultured  MSCs  treated  during  (A)  or  before  (B)  inducing  the 
differentiation. (A) All the treatments seem to enhance the percentage of differentiated cells when 
present in the adipogenic medium. (B) LE135 reduced the number of Nile red positive cells, instead 
ATRA and AC55649 don’t  modify the rate of differentiation. Data show the mean ±sem of two 
independent experiment done in duplicate. 
 
To evaluate the osteogenic differentiation in MSCs culture we measured 
the  activity  of  alkaline  phosphatase,  an  early  marker  of  osteogenic 
differentiation,  and  accumulation  of  calcium  in  the  extracellular  matrix  with 
Alizarin  red  staining,  an  indicator  of  terminal  differentiation  into  osteocyte. 
Treatment  with  ATRA  during  differentiation  increases  the  level  of  alkaline 
phosphatase compared to untreated cells (Fig. 16 A), even if not significantly, but 
no modification of the Alizarin red quantification was seen (Fig. 16 C). On the 
other hand, RARβ agonist enhances alkaline phosphatase activity both during 
and before inducing the differentiation (Fig. 16 A-B), and in the latter case the 
difference is statistically significant (p-value<0.05). Surprisingly, a slight decrease 
of calcium deposition was observed in cells treated with AC55649 either before 
or during differentiation, even if the differences have no statistical significance. 
(Fig.  16  C-D).  Treatment  with  LE135  during  differentiation  does  not  modify 
osteogenic commitment (Fig. 16 A-C), but a reduction in alizarin red staining is 
evident in cells pretreated with RARβ antagonist: this confirms its chondrogenic 
differentiation capacity (Fig. 16 D). Data from pretreated cells show that both 
ATRA and RARβ agonist do not mediate an osteogenic commitment of MSCs (Fig 
16 B and D). 
Taken  together,  data  for  adipogenic  and  osteogenic  differentiation 
confirm that both ATRA and RARβ2 selective agonist do not alter multipotency of 
MSCs or commit them toward a specific lineage. In contrast, the reduction of 
cells terminally differentiated as adipocytes and osteocytes confirms the capacity 
A  B ~ 31 ~ 
of  RARβ  selective  antagonist  LE135  to  induce  chondrogenic  differentiation  of 
MSCs. 
 
 
 
Figure  16:  Alkaline  phosphatase  activity  (A-B)  and  Alizarin  red  staining  (C-D)  quantification  of 
osteogenic  differentiation.  Treatments  were  added  during  (A,  C)  or  before  (B,  D)  inducing 
osteogenesis.  No  relevant  variation  of  the  number  of  osteogenic  cells  were  seen  in  MSCs 
pretreated  with  ATRA  or  RAR
￿  agonist.  LE135  diminishes  the  deposition  of  calcium  in  the 
extracellular  matrix,  confirming  its  role  in  the  chondrogenic  differentiation  of  MSCs.  Data  show 
mean ±sem of three independent experiment done in duplicate. 
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To further investigate the opposite behavior of CFU-F and cultured MSCs 
after  ATRA  treatment,  we  tested  the  expression  level  of  genes  involved  in 
embryonic and adult self-renewal and multipotency (Niwa 2001, Loh 2008).  
Figure 17 shows the expression fold change of all tested genes in CFU-F 
after ATRA treatment. No expression was found for Zfp42/Rex1, Tcl1 and GDF3. 
A  B 
C 
D ~ 32 ~ 
The treatment seems to reduce the expression of Oct4, Nanog, Sox2, Sox15, 
Bmi1,  Utf1  and  KLF4;  in  contrast,  Sall4  level  is  greatly  increased  after  ATRA 
treatment.  No  variation  was  seen  for  the  expression  of  HoxB4.  The  basal 
expression level of Sall4 gene is very low in untreated CFU-Fs, but it becomes 
comparable  to  the  other  self-renewal  genes  after  ATRA  treatment.  This 
phenomenon might be explained by the selection of a specific population in CFU-
F culture that expresses higher level of SALL4 and lower level of all the other 
genes. 
 
 
Figure 17: Expression fold increase of self-renewal genes in CFU-F after treatment with ATRA. 
Values represent the fold increase of mRNA transcript level in treated cells compared to controls. 
Data show mean ±sem of three independent experiments. 
 
The  results  differ  when  the  expression  profile  of  cultured  MSCs  was 
determined. After 8 and 24 hours of treatment, the expression of Oct4, Nanog, 
Sox2, Utf1 and Sall4 increases (Fig. 18 A-E), even if important variations between 
MSCs  derived  from  different  donors  were  noted.  These  five  genes  could  be 
induced after 72 hours, as new fresh medium was added after 2 days of culture. 
In contrast, the expression level of Klf4 is reduced at all the time points, even if 
the lowest values were reached after 24 and 72 hours of treatment (Fig. 18 F). 
No expression was found for Zfp42/Rex1, Tcl1 and GDF3, as in CFU-Fs, and no 
significant variation was seen for Sox15, Bmi1 and HoxB4 mRNA levels. 
 ~ 33 ~ 
 
 
 
Figure 18: expression fold change of Oct4 (A), Nanog (B), Sox2 (C), Utf1 (D), Sall4(E) and Klf4 (F). 
Klf4 seems to be reduced by addition of ATRA to the medium, while Oct4, Nanog, Sox2, Utf1 and 
Sall4  transcripts  augment  in  response  to  the  treatment.  Data  show  the  mean  ±sem  of  four 
independent experiments. 
C 
A  B 
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Retinoic acid plays crucial role in embryogenesis and morphogenesis, and 
it controls cell growth, apoptosis and differentiation of several cell types. Indeed, 
it is used alone or in combination with chemotherapeutic agents to treat acute 
promyelocitic leukemia in vivo (Chomienne 1989, Altucci 2007). Only recently the 
combination  of  ATRA  with  epigenetic  drugs,  such  demethylating  agents  and 
HDAC  inhibitors,  has  been  shown  to  be  effective  against  a  wider  range  of 
hematological  malignancies,  and  clinical  trials  are  in  progress  to  test  the 
therapeutic  effect  of  combination of  all-trans  retinoic  acid,  5-azacytidine  and 
valproic acid in AML patients (Soriano 2007). Mesenchymal stem cells share the 
same microenvironment as hematopoietic stem cells, and they play a central role 
in the balance between proliferation and differentiation of these cells (Lazennec 
2008). In this study, we evaluated the effects of in vitro treatment of ATRA, AZA 
and VPA in human MSC biological properties, such as proliferation, apoptosis, 
senescence and differentiation potential. 
Our data show that treatment with AZA and VPA decreases the number 
of CFU-F in culture. This is consistent with the inhibition of proliferation and 
increase of apoptosis seen in cultured MSCs. In addition, both AZA and VPA alter 
the morphology of cells, that appear more flattened, suggesting the commitment 
towards  a  non-proliferative  or  differentiated  states.  Indeed,  Cho  et  al.  have 
described  an  inhibitory  effect  of  VPA  on  MSC  proliferation  in  culture,  that 
associate  with  a  stimulatory  effect  on  osteogenic  differentiation  (Cho  2005). 
Moreover, it has recently been demonstrated that suberoyl anilide hydroxamic 
acid (SAHA) and MS-275, two synthetic HDAC inhibitors, induce a block in the cell 
cycle along with the induction of apoptotic pathway in human bone marrow-
derived MSCs (Di Bernardo 2009). On the other hand, treatment with AZA alone 
is  sufficient to promote  the  commitment of human  MSCs  in  cardiomyocytes, 
assessed by the expression of cardiac specific markers and functional analysis (Xu 
2004). 
The results reported in this study show a different behavior of CFU-Fs and 
cultured MSCs after ATRA exposure. In fact, ATRA treatment reduces the number 
of colonies in CFU-F assay, whereas it enhances the proliferation rate of cultured 
MSCs. Oliva et al. have first reported a growth inhibition of human MSCs after 
ATRA treatment, due to an accumulation of cells in G1 phase of the cell cycle. ~ 35 ~ 
This  is  probably  linked  with  the  increase  in  the  protein  level  of  the  cyclin-
dependent kinase inhibitors p27
Kip1 and p16
INK4A and the consequent reduction in 
cdk2 activity (Oliva 2003). Cell cycle analysis by flow cytometry did not reveal 
significant variation in the percentage of cell in the active phases of cell cycle 
after ATRA treatment, because the reduction of G2-M cells is compensated by an 
increase  in  the  number  of  cells  in  S  phase.  In  addition,  no  cell  morphology 
changes were observed in cultured MSCs after ATRA treatment as previously 
described (Oliva 2003). The differences in the data collected from our group and 
Oliva’s group might lay on the different methods used to isolate MSCs from bone 
marrow aspirates and to cultivate them. 
The expression levels of the three RARs and RXRs suggest the presence of 
different cell populations in CFU-Fs and cultured MSCs. No expression of RXRγ 
was found in both early and later stem cells: in fact this RXR subtype presents a 
very restricted pattern of expression, mainly in the muscle and certain part of the 
brain (Germain 2006 (2)). RARα and RARγ have a higher expression in CFU-Fs 
compared to MSCs. Furthermore, the RARβ subtype is the only RAR and RXR 
receptor responding to ATRA treatment both in CFU-Fs and cultured MSCs. Both 
RARβ2  and  RARβ4  transcripts  are  induced  by  the  treatment,  albeit  with  no 
change  in the  ratio between  the two  isoforms    in  treated  cells  compared to 
controls.  The  prevalence  of  RARβ2  isoform  suggests  that  it  mediates  ATRA 
signaling in the cells: this hypothesis was validated by the employment of RARβ2 
selective agonist AC55649 (Piu 2005), which exerts the same effect of ATRA on 
proliferation and apoptosis. The crucial role of the RARβ subtype was further 
confirmed by the concurrent treatment of ATRA and a RARβ specific antagonist 
LE135 (Li 1999), that attenuates the proliferation and apoptosis of MSCs with 
ATRA  alone.  The  RARβ2  isoform  is  a  well-known  tumor  suppressor.  Indeed, 
RARβ2  is  frequently  lost  or  epigenetically  silenced  in  various  cancers  and, 
moreover,  its  expression  correlates  inversely  with  tumor  grade  (Xu  2007). 
Furthermore, restoration of RARβ2 expression reactivates RA-dependent growth 
control (Sirchia 2002). However, our data uncover a potential new role of this 
isoform in stimulating MSC proliferation and expansion in culture. 
The ATRA treatment in cultured MSCs might select one of the populations 
present in cultured MSCs. In fact, cells in early passages are heterogeneous in 
morphology,  rates  of  proliferation,  and  efficacy  with  which they differentiate 
(Sekiya  2002).  To  address  this  possibility,  we  checked  the  effect  of  ATRA 
treatment before or during the induction of osteogenesis and adipogenesis. No 
priming towards a specific lineage was found using ATRA or the RARβ2 selective 
agonist; on the contrary, exposure to LE135 reduces the number of adipocyte ~ 36 ~ 
and osteocyte after the induction of differentiation, confirming the role of this 
RARβ  specific  antagonist  in  the  induction  of  chondrogenic  differentiation 
(Kafienah 2007). The presence of ATRA and RARβ2 agonist in osteogenic medium 
enhances alkaline phosphatase activity, even though this is not correlated with 
the deposit of calcium in the extracellular matrix. The absence of concordance 
between alkaline phosphatase and Alizarin red staining data could be due to the 
fact  that  alkaline  phosphatase  is  an  early  marker  of  osteocyte  commitment, 
while calcium deposition in extracellular matrix marks later step of osteogenic 
differentiation. In contrast, Wan and colleagues showed that the presence of 
ATRA  in  osteogenic  medium  stimulate  the  differentiation  of  murine  adipose-
derived  adult  stromal  cells,  confirmed  by  an  increase  in  both  alkaline 
phosphatase  activity  and  Alizarin  red  staining  (Wan  2007).  Specie-specific 
differences and the higher concentration of ATRA used (2.5 µM) could explain 
the  absence  of  ATRA-promoting  effect  in  our  MSC  culture.  Finally,  all  the 
treatments  enhanced  the  percentage  of  adipocytes,  even  if  the  difference  is 
significant only between ATRA-treated and control cells. However, data suggest 
that this phenomenon is not mediated by ATRA or by the activation of RARβ, 
because  the  higher  effect  on  adipocytic  differentiation  was  seen  with  the 
combination ATRA+LE135. Further data are needed to understand the effect of 
these treatments in MSC adipogenesis during the induction of differentiation. 
Finally,  we  tested  the  expression  level  of  genes  known  to  regulate 
embryonic and adult stem cell multipotency and self-renewal. CFU-Fs respond to 
the treatment with a reduction of almost all of the genes tested, except for Sall4. 
Indeed,  Sall4  mRNA  level  is  greatly  induced  by  ATRA  exposure  compared  to 
untreated cells, even if no RARE has been described in its promoter region. The 
selection of a specific population in CFU-Fs culture which expresses high levels of 
Sall4 could explain both the reduction of colony number and the overexpression 
of this gene after ATRA treatment. On the other hand, the expression profile of 
self-renewal genes in cultured MSCs is completely different. In fact, after 8-24 
hours  Oct4,  Nanog  and  Sox2  transcript  levels  are  enhanced  by  ATRA,  with  a 
resultant induction of Utf1 and Sall4 expression, two known target of Oct4 (Niwa 
2001, Loh 2008). The levels of these 5 genes are also increased after 72 hours of 
treatment, maybe in response to the addition of fresh medium containing ATRA, 
but return to baseline levels after 5 days of treatment. Thus, ATRA seems to 
induce a very brief and time-restricted induction of Oct4, Sox2, Nanog, Sall4 and 
Utf1 transcripts, that might explain the proliferative effect on cultured MSCs. In 
contrast, the expression level of Klf4 gene is reduced by ATRA at all the time 
intervals tested. Klf4 protein is necessary for the reprogramming of adult mouse ~ 37 ~ 
fibroblast (Yamanaka 2006), and it shares many common targets with Nanog, 
suggesting a link with the Nanog transcriptional network (Loh 2008). Moreover, 
no variation of the expression of HoxB4 was found both in CFU-Fs and in cultured 
MSCs. This is in marked contrast with the results reported by  Folberg et al. in 
mouse  hindbrain  segmentation,  where  they  demonstrated  the  induction  of 
HoxB4 gene by RARβ in response to RA. (Folberg 1999) In addition, RARβ and 
HoxB4  present  a  direct  crossregulation  for  the  presence  of  RA-  and  Hox-
responsive enhancer in both genes (Serpente 2004). The role of Klf4 and HoxB4 
in MSC maintenance and multipotency is not known, and further studies are 
needed to explain their expression modification in response to ATRA exposure. 
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We demonstrate the inhibitory effect of AZA and VPA treatment in both 
CFU-Fs and cultured MSCs, that correlates with an increase of apoptosis and a 
commitment towards a non-proliferative state. In addition, we show that ATRA 
exposure reduces the number of CFU-Fs, while it enhances the proliferation of 
cultured MSCs without affecting their differentiation potential. RARβ2 isoform 
mediates ATRA signaling both in CFU-Fs and in cultured MSCs, as it is assessed by 
the use of RARβ2 selective agonist and RARβ selective antagonist. Finally, we 
prove that ATRA treatment influence the expression of self-renewal genes in 
early progenitor and MSCs.  
Our data suggest that ATRA selects a specific subpopulation in CFU-Fs 
with  higher  expression  level  of  Sall4.  To  confirm  this  hypothesis,  we  will 
characterize  CFU-Fs  after  ATRA  treatment  by  surface  antigens  and  we  will 
evaluate  the  proliferation,  apoptosis  and  differentiation  potential  of  cultured 
MSCs derived from these colonies.  
The combination of ATRA with epigenetic modifying drugs is now under 
clinical  trial  to  evaluate  its  therapeutic  effect  in  AML  malignancies  (Soriano 
2007). Experiments to analyse whether  MSCs derived from leukemic patients 
respond to ATRA, AZA and VPA treatment in the same way as MSCs from healthy 
donors will be pursued. Our preliminary data confirm that the three drugs trigger 
the  same effect  on  proliferation  and  apoptosis  of  cultured    leukemic patient 
MSCs. In addition, ATRA treatment induces the expression of the RARβ subtype, 
as in normal MSCs. Further studies are needed to confirm these results and to ~ 38 ~ 
compare  the  effect  on  the  differentiation  potential  and  expression  of  self-
renewal genes to normal MSCs. ~ 39 ~ 
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